Overall, our data support that SCD1 downregulation and autophagy impairment may concur to halt the progression of GBM, opening windows for new multimodal therapeutic approaches towards the improvement of the strategies currently in clinical use to fight this aggressive tumor. Here, SCD is linked to neoplasm.